Business
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025
LYON, France, May 13, 2025--MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025
About this update from Maat Pharma
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":442,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/da5932283f07b6f61444d19c6b1e38c9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6o3uZvmOxLT8WAcFVLlcoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTc2NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/da5932283f07b6f61444d19c6b1e38c9","width":442,"height":480}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall Survival of 54%, demonstrating high efficacy and significant clinical improvement over currently available therapies; Positive final DSMB review confirming remarkable efficacy results and a positive benefit/risk profile. Marketing Authorization Application (MAA) in Europe for MaaT013 on track for EMA submission in June 2025.","length":524,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Second safety assessment completed by DSMB with positive outcome and first milestone of unblinded interim safety review reached for Phase 2b trial of MaaT033 for patients receiving allo-HSCT; both reviews concluded positively with the recommendation that the trial proceed without modification.","length":294,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"EAP Revenues of €1.1 million in Q1 2025, a 37,5% increase over Q1 2024.","length":71,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"As of March 31, 2025, cash and cash equivalents were €24.4 million, taking into account the capital increase of March 2025 of €13 million supported by historical shareholders; cash runway into October 2025.","length":206,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":1095,"olType":false},{"type":"text","content":"LYON, France, May 13, 2025--(BUSINESS WIRE)--Regulatory News:","length":61,"tagName":"p"},{"type":"text","content":"MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulat...